Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 46

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 46
---
 20% 16% Current FY to FY+2 CAGR Current FY to FY+3 CAGR October 2024 (Consensus Estimate)¹ July 2025 (Management Projection)² 16% 21% 24% 25% 30% 32% FY+1 FY+2 FY+3 October 2024 (Consensus Estimate)¹ July 2025 (Management Projection)² Revenue CAGR Adjusted EBITDA Margin

Broadwood Partners, L.P. The Price Is Well Below Alcon’s Prior Offers (Continued) 64 6 Alcon reduced its price by much more than STAAR’s prospects have changed, resulting in a dramatically lower multiple Source: FactSet, STAAR proxy statement on Form DEFM14A, filed with the SEC on September 16, 2025, and STAAR Quarterly Reports on Form 10 - Q for the applicable period. 1. Based on consensus estimates as of April 19, 2024 and diluted shares outstanding, cash and equivalents and debt as of the per iod ended March 29, 2024. 2. Based on consensus estimates as of October 29, 2024 and diluted shares outstanding, cash and equivalents and debt as of the p eri od ended September 27, 2024. 3. Based on consensus estimates as of August 4, 2025 and diluted shares outstanding, cash and equivalents and debt as of the per iod ended June 27, 2025. 8.0x 7.2x 6.0x 5.1x 8.2x 8.0x 6.9x 5.9x 4.4x 5.1x 4.0x 3.7x NTM FY FY+1 FY+2 Implied EV / Consensus Revenue Multiple April 2024 Offer¹ October 2024 Offer² Merger Consideration³ (46%) (37%) (42%) (36%)

Broadwood Partners, L.P. We Believe Alcon Could Pay Significantly More for STAAR 65 I think the acquisition of STAAR represents an opportunity for us to take STAAR places they haven't been able to go , won't be able to kind of finance on their own. So, I think we can scale that company and create a lot of synergy around it... So, accretive… [in] a year or two, and really a significant amount